The two therapies demonstrated similar mid-term safety and efficacy, while each cell therapy had its unique advantages and are recommended for certain conditions: for example, PBMNCs for patients with 2 or more critical ischemic limbs and PCCs for patients with significant pain. Credit: AlphaMed Press


Mid-term clinical trial results show similar outcomes in promising cell therapies for CLI


Leave A Reply